ClinicalTrials.gg
CompletedNCT06551181Updated Nov 6, 2026Results posted

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and Placebo (Saline solution) in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 40 sites in 7 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Updated Nov 6, 2026Posted results revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,620
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
3rd of 17
2,620 · median 976
Started
2024
with 6 others
Phase 3
15 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 3rd largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 13th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled from overseas countries that participated in the RSV OA=ADJ-006 (NCT04886596) study, since the vaccine efficacy against lower respiratory tract disease (LRTD) has been demonstrated following a single dose of the RSVPreF3 OA investigational vaccine in the global efficacy study RSV OA=ADJ-006. In addition, the safety (in all participants) , reactogenicity and occurrence of RSV-associated acute respiratory illness (ARI) (in study participants in China only) after administration of the vaccine are also assessed in the current study. No ARI surveillance will be conducted for the overseas participants.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus (RSV)
  • Older adults
  • Acute respiratory illness (ARI)
  • Lower respiratory tract disease (LRTD)
  • Immune response
  • Efficacy study
  • Safety study
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female of ≥60 YOA at the time of study intervention administration, who live in the community dwelling (CD participants).
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, attend regular phone calls/study site visits, perform self-swabbing (study participants in China only), ability to access and utilize a phone or other electronic communications).
  • Participants who are medically stable in the opinion of the investigator at the time of vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.
  • Written or witnessed obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study specific procedure.

Exclusion criteria

Exclusion Criteria:

Medical Conditions:

  • History of any reaction or likely to be exacerbated by any component of the study intervention(s).
  • Any clinical conditions for which serum samples would be prohibited for transfer to local central lab for testing. These clinical conditions include , , and Syphilis based on medical history and physical examination (all participants) and laboratory screening tests (overseas participants).
  • Any confirmed or suspected or immunodeficient condition resulting from disease (e.g., current , human immunodeficiency virus) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat disorders), based on medical history and physical examination (no laboratory testing required).
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Recurrent history or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol (e.g. completion of the diary cards, attend regular phone calls/study site visits, perform self-swabbing (study participants in China only).
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 1 year).
  • Serious or unstable chronic illness.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant Therapy:

  • Previous vaccination with RSV vaccine.
  • Use of any or non-registered product (drug, vaccine or invasive medical device) other than the study intervention(s) during the period beginning 30 days before the dose of study intervention(s), or their planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after study intervention administration, with the exception of COVID-19 and inactivated/subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study intervention.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period (e.g., infliximab).
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the study intervention administration or planned administration during the study period. For , this will mean prednisone >=20 mg/day, or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent Clinical Study Experience:

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).

Other Exclusion Criteria:

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study conduct that prohibits participation until study end.
  • Participation of any study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,620 participants (actual)

Study arms

  • Experimental
    RSV OA vaccine Group (Overseas)

    Overseas older adults (OA) participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6).

    Biological: RSVPreF3 OA investigational vaccine

  • Experimental
    RSV OA vaccine Group (China)

    Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later).

    Biological: RSVPreF3 OA investigational vaccine

  • Experimental
    Placebo Group (China)

    Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later).

    Drug: Placebo (Saline solution)

Interventions

  • One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.

  • DrugPlacebo (Saline solution)

    One dose of placebo is administered intramuscularly at Day 1.

06

What researchers measure

Primary outcomes

  1. RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination

    RSV-A neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.

    Time frame: At Day 31

  2. Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination

    Seroresponse was defined as at least a 4 fold (≥4) increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration).

    Time frame: At Day 31 compared to baseline (Day 1)

  3. RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination

    RSV-B neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.

    Time frame: At Day 31

  4. Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination

    Time frame: At Day 31 compared to baseline (Day 1)

Secondary outcomes

  1. RSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination

    Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

    Time frame: At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)

  2. RSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination

    Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

    Time frame: At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)

  3. Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month and 6 Months Post RSVPreF3 OA Vaccination

    Time frame: At Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination) compared to baseline (Day 1)

  4. RSV-A and RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group

    This outcome measure compares the adjusted GMTs for RSV-A and RSV-B for the RSV OA vaccine Group (China) to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\]. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.

    Time frame: At Day 31

  5. Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group

    This outcome measure compares the seroresponse for RSV-A and RSV-B neutralizing titers in the RSV OA vaccine Group (China) group to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\].

    Time frame: At Day 31 compared to baseline (Day 1)

  6. Number of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) Cases

    ARI and LRTD were reported based on the case definition. Case definition for ARI: presence of at least 2 respiratory symptoms/signs for at least 24 hours or at least 1 respiratory symptom/sign and 1 systemic symptom/sign for at least 24 hours. Case definition for LRTD: presence of at least 2 lower respiratory symptoms/signs for at least 24 hours including at least 1 lower respiratory sign or at least 3 lower respiratory symptoms for at least 24 hours.

    Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])

  7. Duration of Episodes for RSV-confirmed ARI and LRTD Cases

    Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])

  8. Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases

    Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])

  9. Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed LRTD Cases

    Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])

  10. Number of Participants With RSV-confirmed ARI and LRTD Episodes by Severity

    The severity was measured as mild, moderate or severe. Mild= An ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate=An ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe=An ARI/LRTD episode which prevents normal, everyday activities. Such an event would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

    Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])

  11. Number of Participants With RSV-confirmed ARI and LRTD Episodes by Frailty Status

    The frailty status was evaluated as frail, pre-frail, and fit. Frail=Participants with a walking speed \<0.4 meters per second (m/s) or who were not able to perform the test. Pre-frail=Participants with a walking speed between 0.4-0.99 m/s. Fit=Participants with a walking speed ≥1 m/s.

    Time frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])

  12. Number of Participants Reporting Any Solicited Administration Site Adverse Events

    Assessed solicited administration site adverse events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Day 1 (baseline) to Day 7

  13. Number of Participants Reporting Any Solicited Systemic Adverse Events

    Assessed solicited systemic adverse events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Day 1 (baseline) to Day 7

  14. Number of Participants Reporting Any Unsolicited Adverse Events (AEs)

    An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: Day 1 (baseline) to Day 30

  15. Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs

    An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.

    Time frame: Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)

  16. Number of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs

    pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of the intensity grade or relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.

    Time frame: Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)

07

Results

Posted May 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneRSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)
Started8201199601
Completed8121176589
Not completed82312
Withdrew: Adverse event011
Withdrew: Death220
Withdrew: Lost to follow-up020
Withdrew: Withdrawal by subject61710
Withdrew: Other011

Outcome measures

PrimaryRSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination

RSV-A neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.

Time frame:
At Day 31
Reported as:
Geometric mean · Titer
RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination
TiterRSV OA Vaccine Group (China)RSV OA Vaccine Group (Overseas)
RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination5676.7 (5419.3 to 5946.2)6329.5 (5973.7 to 6706.5)
Statistical analysis
  • RSV OA Vaccine Group (China) vs RSV OA Vaccine Group (Overseas) · ANCOVA · Group gmt ratio: 1.11 · 95% CI 1.04 to 1.20Comparison is done using the group ratio of adjusted GMT (RSV-OA (Overseas)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers).
PrimaryPercentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination

Seroresponse was defined as at least a 4 fold (≥4) increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration).

Time frame:
At Day 31 compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination
Percentage of participantsRSV OA Vaccine Group (China)RSV OA Vaccine Group (Overseas)
Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination77.3 (74.8 to 79.6)76.9 (73.7 to 79.8)
Statistical analysis
  • RSV OA Vaccine Group (China) vs RSV OA Vaccine Group (Overseas) · Group srr difference: -0.39 · 95% CI -4.29 to 3.40Comparison is done using the difference of SRR (RSV-OA (Overseas) -RSV-OA (China)).
PrimaryRSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination

RSV-B neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.

Time frame:
At Day 31
Reported as:
Geometric mean · Titer
RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination
TiterRSV OA Vaccine Group (China)RSV OA Vaccine Group (Overseas)
RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination8072.8 (7710.8 to 8451.9)8286.8 (7826.4 to 8774.3)
Statistical analysis
  • RSV OA Vaccine Group (China) vs RSV OA Vaccine Group (Overseas) · ANCOVA · Group gmt ratio: 1.03 · 95% CI 0.95 to 1.10Comparison is done using the group ratio of adjusted GMT (RSV-OA (Overseas)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers).
PrimaryPercentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination
Time frame:
At Day 31 compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination
Percentage of participantsRSV OA Vaccine Group (China)RSV OA Vaccine Group (Overseas)
Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination69.5 (66.8 to 72.2)70.3 (66.9 to 73.5)
Statistical analysis
  • RSV OA Vaccine Group (China) vs RSV OA Vaccine Group (Overseas) · Group srr difference: 0.75 · 95% CI -3.48 to 4.89Comparison is done using the difference of SRR (RSV-OA (Overseas) -RSV-OA (China))
SecondaryRSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination

Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

Time frame:
At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
Reported as:
Geometric mean · Titer
RSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination
TiterRSV OA Vaccine Group (China)RSV OA Vaccine Group (Overseas)
Day 1 (Baseline)703.3 (674.0 to 733.9)825.8 (776.6 to 878.1)
Day 315523.2 (5254.7 to 5805.5)6604.5 (6194.4 to 7041.7)
Day 1812283.4 (2173.7 to 2398.6)2395.6 (2253.9 to 2546.3)
SecondaryRSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination

Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

Time frame:
At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
Reported as:
Geometric mean · Titer
RSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination
TiterRSV OA Vaccine Group (China)RSV OA Vaccine Group (Overseas)
Day 1 (Baseline)1264.9 (1209.8 to 1322.6)1274.2 (1194.6 to 1359.0)
Day 318073.2 (7680.5 to 8485.9)8286.2 (7766.3 to 8840.9)
Day 1813931.5 (3742.4 to 4130.1)3785.0 (3557.0 to 4027.6)
SecondaryPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month and 6 Months Post RSVPreF3 OA Vaccination
Time frame:
At Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination) compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month and 6 Months Post RSVPreF3 OA Vaccination
Percentage of participantsRSV OA Vaccine Group (China)RSV OA Vaccine Group (Overseas)
RSV-A, Day 3177.3 (74.8 to 79.6)76.9 (73.7 to 79.8)
RSV-A, Day 18136.7 (33.9 to 39.6)34.0 (30.7 to 37.4)
RSV-B, Day 3169.5 (66.8 to 72.2)70.3 (66.9 to 73.5)
RSV-B, Day 18136.7 (33.9 to 39.6)33.5 (30.2 to 36.9)
SecondaryRSV-A and RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group

This outcome measure compares the adjusted GMTs for RSV-A and RSV-B for the RSV OA vaccine Group (China) to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\]. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.

Time frame:
At Day 31
Reported as:
Geometric mean · Titer
RSV-A and RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group
TiterRSV OA Vaccine Group (China)RSV OA Overseas (RSV OA=ADJ-006 Study)
RSV-A5790.3 (5505.8 to 6089.4)8670.5 (8165.7 to 9206.6)
RSV-B7975.1 (7611.5 to 8356.0)10281.3 (9726.6 to 10867.6)
Statistical analysis
  • RSV OA Vaccine Group (China) vs RSV OA Overseas (RSV OA=ADJ-006 Study) · ANCOVA · Group gmt ratio: 1.50 · 95% CI 1.38 to 1.62Comparison is done using the group ratio of adjusted GMT (RSV OA Overseas (RSV OA=ADJ-006 study)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers).
  • RSV OA Vaccine Group (China) vs RSV OA Overseas (RSV OA=ADJ-006 Study) · ANCOVA · Group gmt ratio: 1.29 · 95% CI 1.20 to 1.39Comparison is done using the group ratio of adjusted GMT (RSV OA Overseas (RSV OA=ADJ-006 study)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers).
SecondaryPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group

This outcome measure compares the seroresponse for RSV-A and RSV-B neutralizing titers in the RSV OA vaccine Group (China) group to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \[RSV OA Overseas (RSV OA=ADJ-006 study) group\].

Time frame:
At Day 31 compared to baseline (Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group
Percentage of participantsRSV OA Vaccine Group (China)RSV OA Overseas (RSV OA=ADJ-006 Study)
RSV-A77.3 (74.8 to 79.6)81.6 (78.8 to 84.2)
RSV-B69.5 (66.8 to 72.2)78.6 (75.7 to 81.3)
Statistical analysis
  • RSV OA Vaccine Group (China) vs RSV OA Overseas (RSV OA=ADJ-006 Study) · Group srr difference: 4.33 · 95% CI 0.73 to 7.86Comparison is done using the difference of SRR (RSV OA Overseas (RSV OA=ADJ-006 study) - RSV-OA (China)).
  • RSV OA Vaccine Group (China) vs RSV OA Overseas (RSV OA=ADJ-006 Study) · Group srr difference: 9.07 · 95% CI 5.20 to 12.87Comparison is done using the difference of SRR (RSV OA Overseas (RSV OA=ADJ-006 study) - RSV-OA (China)).
SecondaryNumber of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) Cases

ARI and LRTD were reported based on the case definition. Case definition for ARI: presence of at least 2 respiratory symptoms/signs for at least 24 hours or at least 1 respiratory symptom/sign and 1 systemic symptom/sign for at least 24 hours. Case definition for LRTD: presence of at least 2 lower respiratory symptoms/signs for at least 24 hours including at least 1 lower respiratory sign or at least 3 lower respiratory symptoms for at least 24 hours.

Time frame:
From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Reported as:
Count of participants · Participants
Number of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) Cases
ParticipantsRSV OA Vaccine Group (China)Placebo Group (China)
Any ARI16365
RSV-confirmed ARI02
Any LRTD2913
RSV-confirmed LRTD01
SecondaryDuration of Episodes for RSV-confirmed ARI and LRTD Cases
Time frame:
From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Reported as:
Median · Days
Duration of Episodes for RSV-confirmed ARI and LRTD Cases
DaysPlacebo Group (China)
Duration of RSV-confirmed ARI18.5 (17.0 to 20.0)
Duration of RSV-confirmed LRTD17.0 (17.0 to 17.0)
SecondaryNumber of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases
Time frame:
From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Reported as:
Count of units · Episodes
Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases
EpisodesPlacebo Group (China)
Nasal Congestion2
Rhinorrhea2
Sore Throat2
Cough (new or increased)2
Sputum (new or increased)2
Shortness of breath or dyspnea (new or increased)1
Wheezing (new or increased)0
Crackles0
Rhonchi0
Respiratory rate >=20 breaths/min0
Low or decreased oxygen saturation0
Fever1
Feverishness0
Fatigue2
Body aches0
Headache0
Decreased appetite1
Need for oxygen supplementation0
Need for positive airway pressure therapy0
Need of other types of mechanical ventilation0
Other symptoms or signs0
SecondaryNumber of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed LRTD Cases
Time frame:
From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Reported as:
Count of units · Episodes
Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed LRTD Cases
EpisodesPlacebo Group (China)
Nasal Congestion1
Rhinorrhea1
Sore Throat1
Cough (new or increased)1
Sputum (new or increased)1
Shortness of breath or dyspnea (new or increased)1
Wheezing (new or increased)0
Crackles0
Rhonchi0
Respiratory rate >=20 breaths/min0
Low or decreased oxygen saturation0
Fever1
Feverishness0
Fatigue1
Body aches0
Headache0
Decreased appetite1
Need for oxygen supplementation0
Need for positive airway pressure therapy0
Need of other types of mechanical ventilation0
Other symptoms or signs0
SecondaryNumber of Participants With RSV-confirmed ARI and LRTD Episodes by Severity

The severity was measured as mild, moderate or severe. Mild= An ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate=An ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe=An ARI/LRTD episode which prevents normal, everyday activities. Such an event would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

Time frame:
From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Reported as:
Count of participants · Participants
Number of Participants With RSV-confirmed ARI and LRTD Episodes by Severity
ParticipantsPlacebo Group (China)
RSV-confirmed ARI — Mild1
RSV-confirmed ARI — Moderate1
RSV-confirmed ARI — Severe0
RSV-confirmed LRTD — Mild1
RSV-confirmed LRTD — Moderate0
RSV-confirmed LRTD — Severe0
SecondaryNumber of Participants With RSV-confirmed ARI and LRTD Episodes by Frailty Status

The frailty status was evaluated as frail, pre-frail, and fit. Frail=Participants with a walking speed \<0.4 meters per second (m/s) or who were not able to perform the test. Pre-frail=Participants with a walking speed between 0.4-0.99 m/s. Fit=Participants with a walking speed ≥1 m/s.

Time frame:
From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
Reported as:
Count of participants · Participants
Number of Participants With RSV-confirmed ARI and LRTD Episodes by Frailty Status
ParticipantsPlacebo Group (China)
RSV-confirmed ARI — Frail0
RSV-confirmed ARI — Pre-Frail0
RSV-confirmed ARI — Fit2
RSV-confirmed LRTD — Frail0
RSV-confirmed LRTD — Pre-Frail0
RSV-confirmed LRTD — Fit1
SecondaryNumber of Participants Reporting Any Solicited Administration Site Adverse Events

Assessed solicited administration site adverse events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Day 1 (baseline) to Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Adverse Events
ParticipantsRSV OA Vaccine Group (China)Placebo Group (China)
Pain49725
Erythema883
Swelling820
SecondaryNumber of Participants Reporting Any Solicited Systemic Adverse Events

Assessed solicited systemic adverse events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Day 1 (baseline) to Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Adverse Events
ParticipantsRSV OA Vaccine Group (China)Placebo Group (China)
Arthralgia6711
Fatigue16219
Headache9314
Myalgia12312
Fever303
SecondaryNumber of Participants Reporting Any Unsolicited Adverse Events (AEs)

An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
Day 1 (baseline) to Day 30
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
ParticipantsRSV OA Vaccine Group (China)Placebo Group (China)
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)16570
SecondaryNumber of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs

An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.

Time frame:
Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs
ParticipantsRSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)
Any SAEs285339
Related SAEs022
Fatal SAEs220
SecondaryNumber of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs

pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of the intensity grade or relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.

Time frame:
Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs
ParticipantsRSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)
Any pIMDs231
Related pIMDs001

Adverse events

Collected over Solicited AEs: Day 1 (day of vaccination) up to Day 7. Unsolicited AEs: Day 1 up to Day 30. All-cause mortality, any SAEs, related SAEs, fatal SAEs, any pIMDs, related pIMDs: Day 1 up to study end (Month 6 for oversea participants; Month 6 or or last ARI visit/contact, whichever is later, for participants in China). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSV OA Vaccine Group (Overseas)2/820 (0.2%)28/820 (3.4%)2/820 (0.2%)
RSV OA Vaccine Group (China)2/1,199 (0.2%)53/1,199 (4.4%)640/1,199 (53.4%)
Placebo Group (China)0/601 (0%)39/601 (6.5%)108/601 (18%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventRSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)
PneumoniaInfections and infestations2/8203/11994/601
Arteriosclerosis coronary arteryCardiac disorders0/8206/11991/601
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/8205/11993/601
Deep vein thrombosisVascular disorders3/8200/11990/601
Inguinal herniaGastrointestinal disorders0/8200/11992/601
Cerebral infarctionNervous system disorders0/8203/11992/601
OsteoarthritisMusculoskeletal and connective tissue disorders0/8201/11992/601
HypertensionVascular disorders0/8202/11992/601
ConcussionInjury, poisoning and procedural complications2/8200/11990/601
Acute myocardial infarctionCardiac disorders0/8202/11991/601
Most frequent other events
Showing 10 of 123
Most frequent other events
EventRSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)
Injection site painGeneral disorders0/820497/119925/601
FatigueGeneral disorders0/820164/119919/601
MyalgiaMusculoskeletal and connective tissue disorders0/820125/119912/601
HeadacheNervous system disorders0/82095/119915/601
Injection site erythemaGeneral disorders0/82088/11993/601
Injection site swellingGeneral disorders0/82082/11990/601
ArthralgiaMusculoskeletal and connective tissue disorders0/82069/119911/601
PyrexiaGeneral disorders0/82049/11998/601
Upper respiratory tract infectionInfections and infestations0/82019/119911/601
CoughRespiratory, thoracic and mediastinal disorders0/82012/11992/601

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)RSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)Total
Mean70.5 ± 6.869.8 ± 6.669.9 ± 6.770.1 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)RSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)Total
Female4396183041361
Male3815812971259
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV OA Vaccine Group (Overseas)RSV OA Vaccine Group (China)Placebo Group (China)Total
Asian10611996011906
White70700707
American Indian or Alaskan Native3003
Black or African American4004
08

Study locations

40 sites
  • GSK Investigational Site
    Shanghai, Putuo 200065, China
  • GSK Investigational Site
    Shanghai, Putuo, China
  • GSK Investigational Site
    Shanghai, Shanghai Municipality, China
  • GSK Investigational Site
    Shanghai, 200136, China
  • GSK Investigational Site
    Shanghai, 201620, China
  • GSK Investigational Site
    Shanghai, 201901, China
  • GSK Investigational Site
    Shanghai, China
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00290, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Seinäjoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Tokyo, 160-0017, Japan
  • GSK Investigational Site
    Elblag, 82-300, Poland
  • GSK Investigational Site
    Katowice, 40-282, Poland
  • GSK Investigational Site
    Katowice, 40-600, Poland
  • GSK Investigational Site
    Krakow, 31-501, Poland
  • GSK Investigational Site
    Lodz, 91-363, Poland
  • GSK Investigational Site
    Lublin, 20-362, Poland
  • GSK Investigational Site
    Sochaczew, 96-500, Poland
  • GSK Investigational Site
    Warsaw, 00-215, Poland
  • GSK Investigational Site
    Wroclaw, 50-088, Poland
  • GSK Investigational Site
    Guri-si, 471-701, South Korea
  • GSK Investigational Site
    Incheon, 400-711, South Korea
  • GSK Investigational Site
    Seoul, 152-703, South Korea
  • GSK Investigational Site
    Ávila, 05071, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Burgos, 09006, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Salamanca, 37007, Spain
  • GSK Investigational Site
    Valladolid, 47003, Spain
  • GSK Investigational Site
    Witney, Oxfordshire OX29 4QB, United Kingdom
  • GSK Investigational Site
    Belfast, BT7 2EB, United Kingdom
  • GSK Investigational Site
    Blackpool, FY3 7EN, United Kingdom
  • GSK Investigational Site
    Bristol, BS37 4AX, United Kingdom
  • GSK Investigational Site
    Cambridgeshire, CB7 5JD, United Kingdom
  • GSK Investigational Site
    Hounslow, TW3 3EL, United Kingdom
  • GSK Investigational Site
    Witney, OX28 6JS, United Kingdom
09

References and documents

Publications

  • Guo X, Ning G, Bi D, Damaso S, Dodet M, Huang F, Zhang X, Genco F, Lu H, Zhao J, Jiang L, Wu X, Li X, Yang L, Dezutter N, Sun X, Hu J. Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults >/=60 years of age in China: results from a phase 3 immunobridging trial. Front Immunol. 2026 Sep 3;17:1894773. doi: 10.3389/fimmu.2026.1894773. eCollection 2026. PubMed 42756146 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Apr 2025, 8 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 8 months is close to that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2024
First posted
Aug 13, 2024
StartActual
Aug 5, 2024
Primary completionActual
Apr 24, 2025
CompletionActual
Sep 15, 2025
Results first posted
May 19, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 6, 2026
Sites
1 site added, 1 site removed
Show site
  • GSK Investigational Site · Witney, United Kingdom
Show 1 removed
  • GSK Investigational Site · Eynsham, United Kingdom
Nov 6, 2026
Secondary outcomes
8 edited, 4 removed, 3 description edited
What changed in the outcomes
  • EditedRSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline and, 1 Month and 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 1 (baseline) and Day 31 (1 month post RSVPreF3 OA vaccination) → At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
  • EditedRSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline and, 1 Month and 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 1 (baseline) and Day 31 (1 month post RSVPreF3 OA vaccination) → At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
  • EditedPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers Expressed as Unadjusted GMTs atat 1 Month and 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 181 (6 months post RSVPreF3 OA vaccination) → At Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination) compared to baseline (Day 1)
  • EditedNumber of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) CasesTime frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
  • EditedNumber of Episodes of Each of the Symptoms/Signs Associated Withto RSV-confirmed LRTD CasesTime frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
  • EditedNumber of Participants With RSV-confirmed ARI and LRTD CasesEpisodes by Frailty StatusTime frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
  • EditedNumber of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs up to Data Lock Point of Primary AnalysisTime frame: Day 1 (baseline) up to data lock point of primary analysis (median follow-up: 229 days [min.: 28 days, max.: 338 days) → Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
  • EditedNumber of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs up to Data Lock Point for Primary AnalysisTime frame: Day 1 (baseline) up to data lock point of primary analysis (median follow-up: 229 days [min.: 28 days, max.: 338 days) → Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
  • RemovedPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31 compared to baseline (Day 1)
  • RemovedPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 181 compared to baseline (Day 1)
  • RemovedNumber of Participants Reporting Any SAEs, Related SAEs and Fatal SAEs up to End of StudyTime frame: Throughout the study period (up to 6 months post dose [administered at Day 1 (baseline)])
  • RemovedNumber of Participants Reporting Any pIMDs and Related pIMDs up to End of StudyTime frame: Throughout the study period (up to 6 months post dose [administered at Day 1 (baseline)])
  • DescriptionDuration of Episodes for RSV-confirmed ARI and LRTD Cases: how it is measured was reworded
  • DescriptionNumber of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases: how it is measured was reworded
  • DescriptionNumber of Participants With RSV-confirmed ARI and LRTD Episodes by Severity: how it is measured was reworded
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Posted results revised
    1 site added, 1 site removed
    Show site
    • GSK Investigational Site · Witney, United Kingdom
    Show 1 removed
    • GSK Investigational Site · Eynsham, United Kingdom
    Secondary outcomes 8 edited, 4 removed, 3 description edited
    What changed in the outcomes
    • EditedRSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline and, 1 Month and 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 1 (baseline) and Day 31 (1 month post RSVPreF3 OA vaccination) → At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
    • EditedRSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline and, 1 Month and 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 1 (baseline) and Day 31 (1 month post RSVPreF3 OA vaccination) → At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)
    • EditedPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers Expressed as Unadjusted GMTs atat 1 Month and 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 181 (6 months post RSVPreF3 OA vaccination) → At Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination) compared to baseline (Day 1)
    • EditedNumber of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) CasesTime frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
    • EditedNumber of Episodes of Each of the Symptoms/Signs Associated Withto RSV-confirmed LRTD CasesTime frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
    • EditedNumber of Participants With RSV-confirmed ARI and LRTD CasesEpisodes by Frailty StatusTime frame: From Day 15 and up to study end (6 months post dose [dose administered at Day 1])
    • EditedNumber of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs up to Data Lock Point of Primary AnalysisTime frame: Day 1 (baseline) up to data lock point of primary analysis (median follow-up: 229 days [min.: 28 days, max.: 338 days) → Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
    • EditedNumber of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs up to Data Lock Point for Primary AnalysisTime frame: Day 1 (baseline) up to data lock point of primary analysis (median follow-up: 229 days [min.: 28 days, max.: 338 days) → Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)
    • RemovedPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA VaccinationTime frame: At Day 31 compared to baseline (Day 1)
    • RemovedPercentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 6 Months Post RSVPreF3 OA VaccinationTime frame: At Day 181 compared to baseline (Day 1)
    • RemovedNumber of Participants Reporting Any SAEs, Related SAEs and Fatal SAEs up to End of StudyTime frame: Throughout the study period (up to 6 months post dose [administered at Day 1 (baseline)])
    • RemovedNumber of Participants Reporting Any pIMDs and Related pIMDs up to End of StudyTime frame: Throughout the study period (up to 6 months post dose [administered at Day 1 (baseline)])
    • DescriptionDuration of Episodes for RSV-confirmed ARI and LRTD Cases: how it is measured was reworded
    • DescriptionNumber of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases: how it is measured was reworded
    • DescriptionNumber of Participants With RSV-confirmed ARI and LRTD Episodes by Severity: how it is measured was reworded
    + 4 other changes: identifiers, verification date, data sharing statement and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06551181
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 13, 2024
Start date
Aug 5, 2024
Primary completion
Apr 24, 2025
Completion
Sep 15, 2025
Results posted
May 19, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion